Skip to main content
CITCO

CAR NK-cell mediated targeting of CD19 low cancers

Relapse in cancer patients undergoing CAR therapy can occur due to cancer cells downregulating surface antigens. With CARs utilizing CD19 as a target to locate and eliminate cancers, downregulation of CD19 poses a challenge to CAR-mediated therapy.
We are investigating the potential of CAR NK cells to target cancer cells with low amounts of surface CD19 antigen as a method to overcome relapse in patient cases with downregulated surface CD19 antigen.
 

Last Updated 09.05.2025